Anti‐viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia‐recombinant virus expressing LCMV‐WE nucleoprotein or glycoprotein
- 1 March 1989
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 19 (3), 417-424
- https://doi.org/10.1002/eji.1830190302
Abstract
The viral antigen specificity of primary cytotoxic T cell responses (CTL) of H‐2b, H‐2k, H‐2q, H‐2s, H‐2f and some H‐2‐recombinant mice against lymphocytic choriomeningitis virus (LCMV‐WE isolate) as well as the specificity of some CTL clones and T cell lines was defined on target cells infected with vaccinia‐recombinant virus expressing nucleoprotein (Np) or glycoprotein (Gp). Np was recognized together with H‐2q (Dq), H‐2d (DLd), H‐2s and H‐2b (Db). Gp specificity was restricted to H‐2f and H‐2b (Kb and Db); H‐2k‐restricted CTL anti‐LCMV responses were neither Gp nor Np specific. The anti‐viral protective immunity induced by vaccinia‐Gp or vaccinia‐Np recombinants was evaluated in mice. In vivo protection was T cell mediated by class I restricted Ly‐2 T cells; it correlated well with the CTL specificity defined in vitro. Some of the CTL‐nonresponder H‐2 allele plus Np or H‐2 plus Gp combinations were, however, protected to variable and low degrees by vaccinia‐recombinant viruses, indicating that anti‐viral protection is a more sensitive readout for CTL activity than the in vitro assay. For example, B10.D2 H‐2d mice generated measurable CTL responses only to Np; after immunization with a vaccinia‐Np recombinant, LCMV titers were 104 times lower in spleens than in vaccinia‐primed controls. Although vaccinia‐Gp‐immunized BALB/c mice revealed no CTL activity in vitro, they nevertheless had 102 times lower LCMV titers in spleens than controls. Anti‐viral protection, particularly in low‐responder combinations, was usually short‐lived and diminished after 3 weeks. In a high‐responder situation, protection was of a longer duration (> 8 weeks). Vaccination with vaccinia‐Np or Gp recombinants protected mice against lethal T cell‐mediated lymphocytic choriomeningitis induced by LCMV or prevented the local footpad swelling reaction; these in vivo effects were H‐2 dependent and followed the identical roles established for CTL recognition in vitro.Keywords
This publication has 34 references indexed in Scilit:
- Fine dissection of a nine amino acid glycoprotein epitope, a major determinant recognized by lymphocytic choriomeningitis virus-specific class I-restricted H-2Db cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1988
- The Roles of Influenza Virus Haemagglutinin and Nueleoprotein in Protection: Analysis Using Vaccinia Virus RecombinantsScandinavian Journal of Immunology, 1987
- T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus env Gene RecombinantScience, 1986
- The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptidesCell, 1986
- Induction or prevention of immunopathological disease by cloned cytotoxic T cell lines specific for lymphocytic choriomeningitis virusEuropean Journal of Immunology, 1986
- Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D.The Journal of Experimental Medicine, 1985
- Complete sequence of the S RNA of lymphocytic choriomeningitis virus (WE strain) compared to that of pichinde arenavirusVirus Research, 1985
- Susceptibility to murine lymphocytic choriomeningitis maps to class I MHC genes—a model for MHC/disease associationsNature, 1985
- Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cellsNature, 1984
- Ultrastructure of an influenza virus-specific cytotoxic T-cell clone and its interaction with P815 and macrophage targetsCellular Immunology, 1982